Amarin Corp Plc (AMRN)

[Mr Stockboy]

New 4 July patent CANNOT be copied by generics until the patent runs out.

The above stated, it's why I rarely post because right after informing all of you of a new patent the drum gets beat that generics can copy it. NO THEY CAN NOT! NOT UNTIL THE PATENT LIFE RUNS OUT!

It's no wonder this board is a circus. Amarin has multiple next generation Vascepa-Plus in the works be it for diabetes or CVD, but the drug combination is unique and cannot be copied unless the court throws it out or expiration occurs.

Now go back and read the 4 July patent. It's stellar, even amazing. It opens the door to the diabetes and CVD market.

Amarin's BEST PLAN IS TO CREATE AN EPA COMBINATION DRUG WHICH MAY INCLUDE BUT ALSO MAY GO WELL BEYOND THE ADDITION OF A STATIN. This patent sets the stage. Wake up! As long as the patent stands, generics cannot copy it until it expires. Amarin plans to get there.

I personally believe the next-generation is ESSENTIAL TO VALUING A BUY-OUT. This is beyond Alzheimer's which I still think scientifically has a real opportunity! Friends, don't count Amarin out! It's beaten down, and will likely explode!